Table of Contents
PBM reform is shifting market access from rebate-driven contracting to value-based competition. Learn what pharmaceutical manufacturers should do now.
Edward Kim explains how City of Hope is accelerating clinical trials and expanding access to next-generation cancer care.
Pharma companies face a historic patent cliff. China’s emerging market for drug discovery, clinical trials, and licensing deals can strengthen pipelines.
Health plans spend more on IT every year, but administrative costs keep rising. Here’s how a tech P&L and reinvestment engine close the gap.
